Caplin Point Labs#39; subsidiary inks distribution pact with Xellia Pharmaceuticals for 5 injectables in the US

The first product is expected to be launched shortly, while approvals for the remaining are expected in the next 12-18 months, Caplin Point Laboratories said in a BSE filing.

from Moneycontrol Business News https://ift.tt/2AyS598